**OriGene Technologies, Inc.**
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

# Product datasheet for TR308580

## TTLL12 Human shRNA Plasmid Kit (Locus ID 23170)

### Product data:

| | |
|---|---|
| **Product Type:** | shRNA Plasmids |
| **Product Name:** | TTLL12 Human shRNA Plasmid Kit (Locus ID 23170) |
| **Locus ID:** | 23170 |
| **Synonyms:** | dJ526I14.2 |
| **Vector:** | pRS (TR20003) |
| **E. coli Selection:** | Ampicillin |
| **Mammalian Cell Selection:** | Puromycin |
| **Format:** | Retroviral plasmids |
| **Components:** | TTLL12 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 23170). 5µg purified plasmid DNA per construct<br>29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
| **RefSeq:** | NM_015140, NM_015140.1, NM_015140.2, NM_015140.3, BC001070, BC001070.2, NM_015140.4 |
| **UniProt ID:** | Q14166 |
| **Summary:** | Negatively regulates post-translational modifications of tubulin, including detyrosination of the C-terminus and polyglutamylation of glutamate residues (PubMed:20162578, PubMed:23251473). Also, indirectly promotes histone H4 trimethylation at 'Lys-20' (H4K20me3) (PubMed:23251473). Probably by controlling tubulin and/or histone H4 post-translational modifications, plays a role in mitosis and in maintaining chromosome number stability (PubMed:20162578, PubMed:23251473). During RNA virus-mediated infection, acts as a negative regulator of the DDX58/RIG-I pathway by preventing MAVS binding to TBK1 and IKBKE (PubMed:28011935).[UniProtKB/Swiss-Prot Function] |
| **shRNA Design:** | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |

View online »

**Performance Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).